Cryo Cell International INC Form 4 insider transactions

David Portnoy, Chairman, Co-CEO, a Director and 10% owner of Cryo Cell International Inc, reported multiple transactions in common stock on August 5, 2026.

Cryo-Cell International's Chairman and Co-CEO, David Portnoy, reported new stock option grants and updated his beneficial ownership of common stock and derivative securities.

Cryo-Cell International's Chief Information Officer, Oleg Mikulinsky, reported new stock option grants and existing beneficial ownership of common stock and derivative securities.

Cryo-Cell International Co-CEO Mark L. Portnoy reported new stock option grants and updated his beneficial ownership, including performance-based vesting conditions.

Cryo-Cell International's VP Finance and CFO, Jill M. Taymans, was granted 30,000 stock options with performance-based vesting conditions.

Cryo-Cell International's Chairman and Co-CEO, David Portnoy, reported recent acquisitions of common stock, increasing his beneficial ownership.

Cryo-Cell International Co-CEO David Portnoy increased his direct beneficial ownership of common stock through open market purchases in mid-November 2025.

Cryo-Cell International Inc.'s Chairman and Co-CEO, David Portnoy, increased his direct beneficial ownership by acquiring 5,540 shares of common stock over three days in November 2025.

Cryo-Cell International Co-CEO David Portnoy reported acquiring additional common stock and detailed his extensive beneficial ownership, including various stock options.

Cryo-Cell International Inc. Director Daniel Mizrahi reported the acquisition of 5,300 new stock options with an exercise price of $4.35, vesting monthly from October 21, 2025.

Cryo-Cell International Director Harold D. Berger acquired 5,300 new stock options with an exercise price of $4.35, exercisable on October 21, 2025.

Cryo-Cell International's Chairman and Co-CEO, David Portnoy, increased his direct beneficial ownership of common stock through open market purchases totaling 15,424 shares.

Cryo-Cell International's Chairman and Co-CEO, David Portnoy, significantly increased his beneficial ownership through multiple common stock purchases totaling over $190,000.

Cryo-Cell International Co-CEO David Portnoy filed a Form 4 detailing changes in his beneficial ownership, including the disposition of shares previously held for a child.

Cryo-Cell International's Chairman and Co-CEO, David Portnoy, increased his beneficial ownership by purchasing 39,179 shares of common stock across multiple transactions in late August 2025.

Cryo-Cell International Inc.'s Chairman and Co-CEO, David Portnoy, reported significant open market purchases of common stock, increasing his beneficial ownership.

Cryo-Cell International Inc.'s Chairman and Co-CEO, David Portnoy, acquired 5,826 shares of common stock at $4.1719 per share, increasing his beneficial ownership.

Cryo-Cell International Inc. Director Harold D. Berger exercised stock options to acquire 7,500 shares of common stock, increasing his direct beneficial ownership to 57,901 shares.

Oleg Mikulinsky, Chief Information Officer of Cryo-Cell International Inc., reports acquisition of 10,000 stock options.

Mark Portnoy, Co-CEO of Cryo Cell International, reports the acquisition of 25,000 stock options.

David Portnoy, Chairman and Co-CEO of Cryo Cell International, files a Form 4 detailing changes in beneficial ownership, including the acquisition of new stock options.

Jill M. Taymans, CFO of Cryo-Cell International, reports the acquisition of 10,000 stock options.

Oleg Mikulinsky, Chief Information Officer of Cryo Cell International, acquired 20,000 shares and 20,000 stock options through transactions on November 12, 2024.

Harold Berger, a director at Cryo-Cell International, acquired stock options for 5,300 shares of common stock at an exercise price of $5.82 on October 29, 2024.